ArticleCureus2026
Ultrasound Risk Stratification and Bethesda Cytology for Predicting Malignancy in Thyroid Nodules: A Histopathology-Based Comparative Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid nodules are one of the most frequently seen endocrine conditions in clinical practice and a major challenge in diagnosis, as only a small proportion of them are malignant. The current study aimed to compare the American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS) ultrasonographic classification with the Bethesda cytological category in thyroid nodules with histopathological diagnosis.
methodsOur study was conducted as a hospital-based cross-sectional observational analysis in the Departments of Pathology and Radiodiagnosis at Rajendra Institute of Medical Sciences (RIMS), Ranchi. A total of 50 consecutive patients fulfilling the eligibility criteria were included. Ultrasonographic examination was performed using ACR-TIRADS criteria, and fine needle aspiration cytology (FNAC) findings were interpreted according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Histopathological examination served as the reference standard.
resultsIn our study, the mean age was 33.76 ± 12.85 years, and females constituted 34 (68.0%) cases. TIRADS 3 nodules constituted the largest subgroup with 16 (32.0%) cases. Histopathological examination identified 29 (58.0%) benign lesions and 21 (42.0%) malignant lesions. Bethesda cytology demonstrated superior concordance with histopathology, with a specificity of 100% and excellent diagnostic accuracy with an area under the curve (AUC) of 0.81. In contrast, ACR-TIRADS showed poor discriminatory ability with an AUC of 0.51.
conclusionBethesda cytology showed superior concordance and diagnostic accuracy compared with ultrasonographic ACR-TIRADS classification in predicting malignant thyroid nodules. Combined radiological and cytological evaluation may improve diagnostic certainty and support appropriate surgical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.